Search Results
Jan 13, 2026, 03:26 ET Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ
profile, with no dose-limiting toxicities observed during the dose-escalation phase. Cytokine release syndrome (CRS) occurred in all patients but was limited to Grade 1 or 2, and no Grade ≥3 CRS, ICANS, or treatment-related deaths were reported.In evaluable patients, IMC002 achieved an objective
More news about: Immunofoco Biotechnology
Jan 09, 2026, 16:00 ET Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026
spevatamig + GnP still maturing. Of note: Spevatamig has demonstrated a favorable safety profile. In monotherapy, no CRS or DLTs were observed. The maximum tolerated dose (MTD) has not been reached in either the monotherapy or combination therapy setting. No Grade ≥ 3 treatment-emergent
More news about: Phanes Therapeutics, Inc.
Jan 07, 2026, 08:00 ET CRS, a Reverence Capital Partners Portfolio Company, Announces Sale to Ridgemont Equity Partners
capabilities to CRS. Under Reverence Capital's ownership, CRS also successfully launched its Managed Repair Program in 2024, a new business line that facilitates home repair and restoration services for insurance carriers and their policyholders."Under Reverence Capital's ownership, CRS more than doubled
More news about: Reverence Capital Partners
Jan 06, 2026, 09:30 ET Lung Cancer Research Foundation Announces Additional 2025 Scientific Research Grant Awards
how to predict which patients will benefit from this treatment and who is at higher risk for CRS. The study has two main aims: 1. Predicting who responds to the drug and 2. Identifying who is at risk for CRS in order to develop a new framework for personalizing treatment, making it more effective and
More news about: Lung Cancer Research Foundation
Jan 05, 2026, 06:00 ET Cowbell Announces Next Cycle of Growth, Profitability, and Global Expansion; Appoints John Botros as Chief Financial Officer
in commercial and specialty lines, including cyber, technology errors and omissions, and management liability. Through Cowbell Resiliency Services (CRS)—an independent cybersecurity advisory arm—policyholders gain access to Digital Forensics and Incident Response (DFIR) services as well as proactive solutions,
More news about: Cowbell
Dec 28, 2025, 19:10 ET CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596
lymphodepletion), 1 achieved very good partial response (VGPR), and 2 achieved PR. Four patients experienced Grade 1 cytokine release syndrome (CRS), with no Grade 2 or higher CRS observed. No immune effector cell-associated neurotoxicity syndrome (ICANS), GvHD, dose-limiting toxicities, treatment discontinuations,
More news about: CARsgen Therapeutics
Dec 19, 2025, 07:44 ET Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
with high-risk relapse and patients with primary CNS relapse. Consistent with our experience in the adult population, data show low rates of severe CRS and ICANS."Autolus also presented post-hoc analyses from the FELIX pivotal trial demonstrating that CAR T-cell persistence at three months
More news about: USA News Group
Dec 16, 2025, 20:00 ET Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma
for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies
More news about: Antengene Corporation Limited
Dec 12, 2025, 17:45 ET Dominari Holdings Announces Change of Record Date and Payment Date for $10 Million Cash Dividend
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Dec 12, 2025, 09:00 ET Roivios Reports Promising Results from First-in-Human Trial of JuxtaFlow® Renal Assist Device
novel therapy has shown potential to improve outcomes for patients with acute decompensated heart failure and diuretic-resistant cardiorenal syndrome (CRS).
More news about: Roivios, ltd
Dec 11, 2025, 07:00 ET Dominari Holdings Announces $10 Million Cash Dividend
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Dec 09, 2025, 11:15 ET Airiver Medical Secures IDE Approval from the FDA for Pivotal Clinical Study of the Airiver Drug Coated Balloon for Patients with Chronic Rhinosinusitis
officer for Airiver Medical.CRS is defined as long-term (present for a minimum of three months despite intervention) symptomatic inflammation of the nose and paranasal sinuses. CRS is one of the most common chronic medical conditions in the world. For many CRS sufferers, medication alone is not
More news about: Airiver Medical
Dec 09, 2025, 08:44 ET Mamba Brand CEO Claims FDA & DEA Lack Funding and Law Enforcement Capacity to Enforce New Hemp Ban
funding, staffing, and federal infrastructure, according to a newly released congressional analysis. The Congressional Research Service (CRS)—the nonpartisan investigative office that advises U.S. lawmakers—issued a report warning that both the Food and Drug Administration (FDA) and
More news about: The Mamba Brand LLC
Dec 09, 2025, 07:44 ET Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
release syndrome (CRS), including life-threatening or fatal reactions. In the clinical trial, CRS occurred in 72% of patients who received TECVAYLI® at the recommended dose, with Grade 1 CRS occurring in 50% of patients, Grade 2 in 21%, and Grade 3 in 0.6%. Recurrent CRS occurred in 33% of
More news about: Johnson & Johnson
Dec 09, 2025, 07:30 ET Tec-Dara Combination Offers Substantial Improvement Over Standard Second-Line Therapies for Relapsed or Refractory Multiple Myeloma
researchers noted that strategies for managing infections also improved over the course of the study. Low-grade cytokine release syndrome (CRS) was also common, with grade 1-2 CRS occurring in 60.1% of those receiving Tec-Dara.One limitation of the study is that patients refractory to daratumumab were
More news about: American Society of Hematology
Dec 08, 2025, 08:30 ET Dominari Expands Strategic Leadership with Appointment of Ambassador Jamie McCourt to Advisory Board
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Dec 07, 2025, 21:08 ET CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
deepening response to VGPR.CT0596 demonstrated a manageable safety profile. Four patients experienced Grade 1 cytokine release syndrome (CRS); no Grade 2 or higher CRS was observed. No immune effector cell-associated neurotoxicity syndrome (ICANS) or graft-versus-host disease (GVHD) was reported. No dose-limiting
More news about: CARsgen Therapeutics
Dec 07, 2025, 20:57 ET IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH
achieving stringent complete response (sCR).After infusion of Eque-cel, cytokine release syndrome (CRS) occurred in 11 patients (68.8%), all of which were grade 1-2. The median time to CRS onset was 7 days, with a median duration of 3 days. No neurotoxic effects or immune effector cell-associated
More news about: IASO Bio
Dec 07, 2025, 20:02 ET ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
recoverable.The incidences of CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) were 64.1% and 6.1%, respectively, all of which were Grade 1-2 and resolved with treatment. Prophylactic use of tocilizumab may reduce incidence, severity, and duration CRS.The incidence of all-grade
More news about: Innovent Biologics
Dec 07, 2025, 19:15 ET CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
response to VGPR. CT0596 demonstrated a manageable safety profile. Four patients experienced Grade 1 cytokine release syndrome (CRS); no Grade 2 or higher CRS was observed. No immune effector cell-associated neurotoxicity syndrome (ICANS) or graft-versus-host disease (GVHD) was reported. No dose-limiting
More news about: CARsgen Therapeutics
Dec 07, 2025, 07:30 ET Studies Point to a Growing Role for New Therapies and Immunotherapies in Treating Blood Cancers
3 or 4 cytokine release syndrome (CRS). According to researchers, this suggests that the combined regimen is safe to administer in a variety of medical settings."There has been some hesitancy to use bispecific antibodies in a community setting because of CRS," said Dr. Falchi. "The prospect of
More news about: American Society of Hematology
Dec 07, 2025, 04:21 ET CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue
manageable safety profile and deep, durable efficacy in patients with relapsed/refractory multiple myeloma. No grade 3 or higher cytokine release syndrome (CRS) was observed. No immune effector cell-associated neurotoxicity syndrome (ICANS), delayed neurotoxicities, second primary malignancy, or other delayed
More news about: CARsgen Therapeutics
Dec 06, 2025, 09:30 ET Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
life-threatening, occurred following treatment with CARVYKTI®, including before CRS onset, concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with CARVYKTI®. Provide
More news about: Johnson & Johnson
Dec 05, 2025, 12:05 ET MLG CAPITAL'S DAVID RODRIGUEZ HONORED WITH MHN EXCELLENCE AWARD IN THE RISING STAR CATEGORY
FINRA/SIPC. Its Form CRS may be found
More news about: MLG Capital
Dec 04, 2025, 08:10 ET ProPharma Welcomes Dan Ryan as President of Clinical Research Solutions
Clinical Research Solutions (CRS). In this role, Dan will be responsible for leading ProPharma's full-service clinical trials service line.
More news about: ProPharma Group Holdings LLC